These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3103493)

  • 1. Transfer from immediate-release disopyramide to controlled-release disopyramide.
    DiPersio DM; Chow MS
    Angiology; 1987 Feb; 38(2 Pt 2):188-91. PubMed ID: 3103493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic evaluation of standard and controlled-release disopyramide.
    Siddoway LA; Barbey JT; Roden DM; Woosley RL
    Angiology; 1987 Feb; 38(2 Pt 2):184-7. PubMed ID: 3103492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term use of controlled-release disopyramide in patients with severe ventricular arrhythmias.
    Paulk EA
    Angiology; 1987 Feb; 38(2 Pt 2):198-204. PubMed ID: 3103494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative absorption of disopyramide as determined by liquid chromatography following acute administration of standard capsules and controlled-release tablets.
    Graffner C; Lagerström PO; Lundborg PN; Rönn OF
    Int J Clin Pharmacol Ther Toxicol; 1981 Sep; 19(9):414-9. PubMed ID: 7298249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias.
    Capparelli EV; DiPersio DM; Zhao H; Kluger J; Chow MS
    J Clin Pharmacol; 1988 Apr; 28(4):306-11. PubMed ID: 3392228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Delayed-action disopyramide in the treatment of hyperkinetic ventricular arrhythmia. A randomized clinical comparative study vs immediate-action disopyramide].
    Romanò M; Spinelli A; Cazzani E; Muzio L
    Clin Ter; 1991 Jul; 138(1):13-9. PubMed ID: 1834395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
    Lien E; Bakke OM
    Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and tolerability of sustained-release disopyramide in the treatment of cardiac arrhythmia. Results of a study with 593 patients].
    Lekieffre J; Vaur L; Kacet S; Lacroix D
    Ann Cardiol Angeiol (Paris); 1993 Feb; 42(2):115-9. PubMed ID: 8494319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of the effectiveness and stability of action of sustained-release disopyramide phosphate by the Holter method].
    de Lombera Romero F; Martínez-Osorio Corzan L; Seoane J; Franco JR
    Rev Esp Cardiol; 1985; 38(6):446-50. PubMed ID: 2419948
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation.
    Zema MJ
    Ther Drug Monit; 1984; 6(2):192-8. PubMed ID: 6740739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism.
    Tennezé L; Tarral E; Ducloux N; Funck-Brentano C
    Clin Pharmacol Ther; 2002 Aug; 72(2):112-22. PubMed ID: 12189358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous disopyramide in acute myocardial infarction: a haemodynamic and pharmacokinetic study.
    Cameron J; Stafford W; Pritchard D; Norris R; Ravenscroft P
    J Cardiovasc Pharmacol; 1984; 6(1):126-31. PubMed ID: 6199595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical scope of disopyramide seven years after introduction--an overview.
    Willis PW
    Angiology; 1987 Feb; 38(2 Pt 2):165-73. PubMed ID: 2435196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance therapy after i.v. administration of disopyramide with an oral sustained release preparation, a pharmacokinetic study.
    Liem KL; Hollander JM
    Br J Clin Pharmacol; 1984 Aug; 18(2):226-8. PubMed ID: 6487461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate- versus controlled-release disopyramide: importance of saturable binding.
    Davies RF; Siddoway LA; Shaw L; Barbey JT; Roden DM; Woosley RL
    Clin Pharmacol Ther; 1993 Jul; 54(1):16-22. PubMed ID: 8330460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation.
    Hing JP; Piotrovsky V; Kimko H; Brashear HR; Zhao Q
    Curr Med Res Opin; 2005 Apr; 21(4):483-8. PubMed ID: 15899095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
    Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
    Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of total and unbound disopyramide: implications for clinical use of the immediate and controlled-release dosage forms.
    Piscitelli DA; Fischer JH; Schoen MD; Hoon TJ; Bauman JL
    J Clin Pharmacol; 1994 Aug; 34(8):823-8. PubMed ID: 7962670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical scope of disopyramide. A clinical symposium. San Antonio, Texas, November 5, 1984. Proceedings.
    Angiology; 1987 Feb; 38(2 Pt 2):165-204. PubMed ID: 3103490
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacokinetics of anti-arrhythmics. 2. Clinical applications].
    Lévy RH; Lévy S; Bricaud H
    Arch Mal Coeur Vaiss; 1980 Oct; 73(10):1229-35. PubMed ID: 6778416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.